A Phase 2 interventional study of Lenalidomide in T-cell Non-Hodgkin's Lymphoma, sponsored by Celgene. Terminated at 45 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-25.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing lenalidomide in Lymphoma, T-Cell — none open to participants now, none under way, none of them phase 3. Lenalidomide · Lymphoma, T-Cell.
Among the 13 studies testing lenalidomide in Lymphoma, T-Cell, this one is the 5th largest by enrollment, is one of 2 that started in 2008, is one of 6 in phase 2, and was the 2nd registered.
310 studies on the registry are indexed under Lymphoma, T-Cell; 77 are open to participants now.
Browse Lymphoma, T-Cell studies →None of the 13 studies testing lenalidomide in Lymphoma, T-Cell is open now. The open studies under Lymphoma, T-Cell, anywhere →
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 67 Lymphoma, T-Cell studies recruiting now, 41 (61%) set no upper age limit and 20 (30%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9
First in 2006; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is above the median of 37 across 270 interventional studies indexed under Lymphoma, T-Cell.
Median enrollment 41 across the 13 interventional studies. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 13 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
Bristol-Myers Squibb has 4 studies filed under Lymphoma, T-Cell — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing lenalidomide in Lymphoma, T-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase II, multicenter, single-arm, open-label study of oral lenalidomide monotherapy administered to subjects with relapsed or refractory T-cell lymphoma. This study will be conducted in two phases: a Treatment Phase and a Follow-up Phase.
Subjects who qualify for enrollment into the study will enter the Treatment Phase and receive single-agent lenalidomide 25 mg once daily on Days 1-21 every 28 days (28-day cycles). Subjects may continue participation in the Treatment Phase of the study for a maximum duration of 24 months, or until disease progression or unacceptable adverse events develop.
All subjects who discontinue the Treatment Phase for any reason will continue to be followed until progression of disease or until next lymphoma treatment is given, whichever comes first, during the Follow-up Phase.
Objectives:
Primary:
Secondary:
Study was terminated. Study data assessment revealed that study drug is active, but is not likely to be sufficiently active as a single agent in this population for registration purposes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-proven T-cell Non-Hodgkin's Lymphoma, either:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label, oral lenalidomide monotherapy
Drug: Lenalidomide
Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle
Also known as: Revlimid
Participants Categorized by Best Response as Determined by Investigator
Participant response assessed by investigator; criteria by B. Cheson in Journal of Clinical Oncology, 1999 (see article for more detail): * Complete Response(CR): Complete disappearance of all detectable disease * Complete Response Unconfirmed(CRu): CR, but indeterminate bone marrow * Partial Response(PR): \>50% decrease in six largest nodes/nodal masses * Stable Disease(SD): Less than PR, but not progressive disease * Relapsed Disease: In CR/CRu Patients, new lesions seen or increased by \>=50% in previous sites * Progressive Disease(PD): \>=50% increase from low in PR/Non-Responders
Time frame: Up to 24 months
Duration of Response
Kaplan-Meier Estimate of duration of response calculated as the time from first computed tomography (CT) Scan or magnetic resonance imaging (MRI) that demonstrates at least a partial response to the first documentation of disease progression, including death due to Non-Hodgkin's Lymphoma.
Time frame: Up to 24 months
Time-to-Progression
Kaplan-Meier estimate of time-to-progression is calculated as the time from the start of study drug therapy to the first documentation of progressive disease.
Time frame: Up to 24 months
Progression-Free Survival
Kaplan-Meier estimate of progression-free survival is defined as the start of study drug therapy to the first observation of disease progression or death due to any cause.
Time frame: Up to 24 months
Safety
Summary of Treatment-Emergent Events in Safety Population (participants with at least one dose of study drug). Events assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE, Version 3: Following is the scale: Grade 1=Mild Adverse Event (AE), Grade 2=Moderate AE, Grade 3=Severe and Undesirable AE, Grade 4=Life-threatening or Disabling AE, and Grade 5=Death Related to AE.)
Time frame: Up to 24 months
Recruiting began March 2008; first participant enrolled 16 June 2008 and last participant enrolled 29 January 2010.
| Milestone | Single Agent Lenalidomide |
|---|---|
| Started | 54 |
| Completed | 0 |
| Not completed | 54 |
| Withdrew: Adverse event | 6 |
| Withdrew: Death | 5 |
| Withdrew: Disease progression | 27 |
| Withdrew: Study terminated | 9 |
| Withdrew: Other | 1 |
| Withdrew: New lymphoma treatment started | 4 |
| Withdrew: Withdrawal by subject | 2 |
Participant response assessed by investigator; criteria by B. Cheson in Journal of Clinical Oncology, 1999 (see article for more detail): * Complete Response(CR): Complete disappearance of all detectable disease * Complete Response Unconfirmed(CRu): CR, but indeterminate bone marrow * Partial Response(PR): \>50% decrease in six largest nodes/nodal masses * Stable Disease(SD): Less than PR, but not progressive disease * Relapsed Disease: In CR/CRu Patients, new lesions seen or increased by \>=50% in previous sites * Progressive Disease(PD): \>=50% increase from low in PR/Non-Responders
| Participants | Single Agent Lenalidomide |
|---|---|
| Complete Response (CR) | 4 |
| Complete Response Unconfirmed (CRu) | 2 |
| Partial Response (PR) | 6 |
| Stable Disease (SD) | 16 |
| Progressive Disease (PD) | 16 |
| No Response Assessment | 9 |
| Other | 1 |
| Tumor Control (CR+CRu+PR+SD) | 28 |
Kaplan-Meier Estimate of duration of response calculated as the time from first computed tomography (CT) Scan or magnetic resonance imaging (MRI) that demonstrates at least a partial response to the first documentation of disease progression, including death due to Non-Hodgkin's Lymphoma.
| Months | Single Agent Lenalidomide |
|---|---|
| Duration of Response | 3.55 (3.1562 to 7.6274) |
Kaplan-Meier estimate of time-to-progression is calculated as the time from the start of study drug therapy to the first documentation of progressive disease.
No measurements were reported for this outcome.
Kaplan-Meier estimate of progression-free survival is defined as the start of study drug therapy to the first observation of disease progression or death due to any cause.
| Months | Single Agent Lenalidomide |
|---|---|
| Progression-Free Survival | 2.53 (1.7753 to 4.6356) |
Summary of Treatment-Emergent Events in Safety Population (participants with at least one dose of study drug). Events assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE, Version 3: Following is the scale: Grade 1=Mild Adverse Event (AE), Grade 2=Moderate AE, Grade 3=Severe and Undesirable AE, Grade 4=Life-threatening or Disabling AE, and Grade 5=Death Related to AE.)
| Participants | Single Agent Lenalidomide |
|---|---|
| At least 1 adverse event (AE) | 53 |
| At least 1 AE related to drug | 40 |
| At least 1 NCI CTCAE Grade 3-4 AE | 34 |
| At least 1 NCI CTCAE Gr 3-4 AE related to drug | 19 |
| At least 1 serious adverse event (SAE) | 29 |
| At least 1 SAE related to drug | 16 |
| At least 1 AE leading to drug withdrawal (WD) | 21 |
| At least 1 AE leading to drug interruption/WD | 19 |
Collected over Up to 24 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single Agent Lenalidomide | — | 29/54 (53.7%) | 53/54 (98.1%) |
| Event | Single Agent Lenalidomide |
|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/54 |
| NeutropeniaBlood and lymphatic system disorders | 3/54 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/54 |
| General Physical Health DeteriorationGeneral disorders | 3/54 |
| PneumoniaInfections and infestations | 3/54 |
| AnaemiaBlood and lymphatic system disorders | 2/54 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/54 |
| AstheniaGeneral disorders | 2/54 |
| PyrexiaGeneral disorders | 2/54 |
| SepsisInfections and infestations | 2/54 |
| Event | Single Agent Lenalidomide |
|---|---|
| PyrexiaGeneral disorders | 14/54 |
| ConstipationGastrointestinal disorders | 12/54 |
| AstheniaGeneral disorders | 11/54 |
| ThrombocytopeniaBlood and lymphatic system disorders | 10/54 |
| NeutropeniaBlood and lymphatic system disorders | 9/54 |
| DiarrhoeaGastrointestinal disorders | 8/54 |
| Oedema PeripheralGeneral disorders | 8/54 |
| AnaemiaBlood and lymphatic system disorders | 7/54 |
| NauseaGastrointestinal disorders | 7/54 |
| DysphagiaGastrointestinal disorders | 6/54 |
| Age, Continuous(years) | Single Agent Lenalidomide |
|---|---|
| Mean | 63.2 ± 11.25 |
| Age, Customized(participants) | Single Agent Lenalidomide |
|---|---|
| <=18 years | 0 |
| >18 years and < = 65 years | 28 |
| >65 years | 26 |
| Sex: Female, Male(Participants) | Single Agent Lenalidomide |
|---|---|
| Female | 18 |
| Male | 36 |
| Race/Ethnicity, Customized(participants) | Single Agent Lenalidomide |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian/Pacific Islander | 3 |
| Black | 4 |
| Hispanic | 1 |
| White | 45 |
| Other | 1 |
| Missing | 0 |
| Region of Enrollment(participants) | Single Agent Lenalidomide |
|---|---|
| France | 40 |
| United States | 3 |
| Belgium | 3 |
| Australia | 8 |
| Non-Hodgkin's Lymphoma Diagnosis/Histopathology(Participants) | Single Agent Lenalidomide |
|---|---|
| Anaplastic large cell lymphoma, primary cutaneous | 1 |
| Anaplastic large cell lymphoma, primary systemic | 3 |
| Angioimmunoblastic T-cell lymphoma | 26 |
| Cutaneous T-cell lymphoma, mycosis fungoides var. | 3 |
| Extranodal NK T-cell lymphoma, nasal type | 1 |
| Peripheral T-cell lymphoma, not otherwise charac | 20 |
Ran from Mar 2008 to primary completion in Mar 2010, 24 months.
Results were first posted in Jan 2012, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide